Raj Bhikhu Parekh
Director/Board Member chez AURA BIOSCIENCES, INC.
Fortune : 125 600 $ au 31/03/2024
Provenance du réseau au premier degré de Raj Bhikhu Parekh
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
University of Oxford
87
| College/University | Other Consumer Services | 87 |
43
| Public Company | Biotechnology | 43 |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.
42
| Private Company | Investment Managers | 42 |
| Public Company | Biotechnology | 26 | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland.
19
| Subsidiary | Medical Specialties | 19 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA.
18
| Extinct | Medical Specialties | 18 |
| Public Company | Biotechnology | 14 | |
Oxford GlycoSciences Plc
 Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK.
13
| Extinct | Pharmaceuticals: Major | 13 |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Ploughshare Innovations Ltd.
 Ploughshare Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services Ploughshare Innovations Ltd. provides technology development and transfer services for the United Kingdom ministry of defense. The firm offers technologies to the life science, defence, cyber, biometrics, detection, diagnostics and electronics industries. The company was founded on March 22, 2002 and is headquartered in Stockbridge, the United Kingdom.
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson.
8
| Holding Company | Biotechnology | 8 |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom.
7
| Holding Company | Pharmaceuticals: Generic | 7 |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The private company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.
6
| Subsidiary | Biotechnology | 6 |
Rappta Therapeutics Oy
 Rappta Therapeutics Oy BiotechnologyHealth Technology Rappta Therapeutics Oy operates as a biopharmaceutical company. It develops anti-cancer drugs activating protein phosphatase 2A. The company was founded by Goutham Narla and Mikko Lauri Sampsa Mannerkoski on March 20, 2019 and is headquartered in Helsinki, Finland.
6
| Holding Company | Biotechnology | 6 |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.
5
| Subsidiary | Drugstore Chains | 5 |
Capella Bioscience Ltd.
 Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Novartis Venture Fund
 Novartis Venture Fund Investment ManagersFinance Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.
3
| Venture Capital Fund | Investment Managers | 3 |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Alpha Anomeric SAS
 Alpha Anomeric SAS Pharmaceuticals: MajorHealth Technology Alpha Anomeric SAS Develops genetic medicines for severe neuromuscular diseases. The company is headquartered in Paris, France.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Raj Bhikhu Parekh via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Executive Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Executive Officer | |
| VODAFONE GROUP PLC | Wireless Telecommunications | Sales & Marketing Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal President | |
| SANOFI | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Corporate Officer/Principal | |
| MDXHEALTH SA | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Chairman | |
| OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Equipment/Instruments | Director/Board Member Founder | |
| ACUTUS MEDICAL, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Director/Board Member Corporate Officer/Principal | |
| Brown University | College/University | Doctorate Degree Undergraduate Degree | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Masters Business Admin Masters Business Admin Graduate Degree Masters Business Admin | |
| University of Pennsylvania | College/University | Undergraduate Degree Doctorate Degree | |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Founder Chief Tech/Sci/R&D Officer | |
| Imperial College London | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Director/Board Member Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin | |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools. | College/University | Director/Board Member Masters Business Admin | |
| University of California, Berkeley | College/University | Doctorate Degree Undergraduate Degree | |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Director/Board Member Doctorate Degree | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
| ABLYNX | Biotechnology | Director/Board Member Investor Relations Contact Corporate Officer/Principal | |
| University College London | College/University | Undergraduate Degree Doctorate Degree | |
| University of Leiden | College/University | Corporate Officer/Principal Undergraduate Degree | |
| Ghent University | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Masters Business Admin | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Chairman Chairman | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | President Director/Board Member | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Medical Distributors | Director/Board Member Chairman | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chairman Director/Board Member Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer Chief Operating Officer Director/Board Member | |
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Private Equity Investor | |
| PROQR THERAPEUTICS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree | |
| ARAVIVE, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| EDITAS MEDICINE, INC. | Biotechnology | Director of Finance/CFO Chief Executive Officer | |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 21 |
| Belgique | 14 |
| Royaume-Uni | 11 |
| Pays-Bas | 5 |
| France | 2 |
Sectorielle
| Health Technology | 25 |
| Consumer Services | 16 |
| Commercial Services | 6 |
| Finance | 4 |
| Communications | 2 |
Opérationnelle
| Director/Board Member | 465 |
| Corporate Officer/Principal | 177 |
| Chairman | 94 |
| Independent Dir/Board Member | 94 |
| Chief Executive Officer | 82 |
Relations les plus connectées
| Insiders | |
|---|---|
| Daniel Geffken | 53 |
| Christopher Viehbacher | 37 |
| Rudi Mariën | 31 |
| Len Blavatnik | 28 |
| Patrick Pichette | 26 |
| Wendy Becker | 25 |
| Mohammed Malik | 24 |
| Jérôme Contamine | 23 |
| Kevin Johnson | 22 |
| Dale Pfost | 22 |
| Fiona MacLaughlin | 22 |
| Julie Baddeley | 21 |
| Sapna R. Srivastava | 21 |
| Rudi Pauwels | 19 |
| Daniel O'Day | 19 |
- Bourse
- Insiders
- Raj Bhikhu Parekh
- Connexions Sociétés
